EGFR and HER3 mRNA expression levels predict distant metastases in locally advanced rectal cancer

International Journal of Cancer

Volumn 128, Issue 12, 2011, Pages 2938-2946

  Ho Pun Cheung, Alexandre ^a,b   Assenat, Eric ^a   Bascoul Mollevi, Caroline ^a   Bibeau, Frédéric ^a   Boissiãre Michot, Florence ^a   Cellier, Dominic ^b   Azria, David ^a   Rouanet, Philippe ^a   Senesse, Pierre ^a   Ychou, Marc ^a   Lopez Crapez, Evelyne ^a,c  

^a CENTRE VAL D AURELLE   (France)

^b Merck KGaA France   (France)

^c INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

Author keywords

distant metastases; HER signalling pathway; prognostic marker; rectal cancer

Indexed keywords

B RAF KINASE; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; MESSENGER RNA; ONCOPROTEIN; OXALIPLATIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN HER3; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALLELE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; GENE FREQUENCY; GENE LOSS; GENE MUTATION; GENE OVEREXPRESSION; GENETIC CORRELATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECTUM CANCER; SIGNAL TRANSDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; CHROMOSOME DELETION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-3; RECTAL NEOPLASMS; RNA, MESSENGER;

EID: 79955373880     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25639     Document Type: Article

References (45)

1. Zampino MG, Labianca R, Beretta GD, Magni E, Gatta G, Leonardi MC, Chiappa A, Biffi R, de Braud F, Wils J,. Rectal cancer. Crit Rev Oncol Hematol 2008; 70: 160-82.
2. Camilleri-Brennan J, Steele R,. The impact of recurrent rectal cancer on quality of life. Eur J Surg Oncol 2001; 27: 349-53. (Pubitemid 32624535)
3. Galandiuk S, Wieand HS, Moertel CG, Cha SS, Fitzgibbons RJ, Pemberton JH, Wolff BG,. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet 1992; 174: 27-32.
4. Heald RJ, Husband EM, Ryall RD,. The mesorectum in rectal cancer surgery-the clue to pelvic recurrence? Br J Surg 1982; 69: 613-6. (Pubitemid 12038080)
5. Bosset J, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier J,. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355: 1114-23. (Pubitemid 44394918)
6. Gérard J, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin M, Untereiner M, Leduc B, Francois E, Maurel J, Seitz J, Buecher B, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006; 24: 4620-5. (Pubitemid 46630960)
7. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens J, Liersch T, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-40.
8. Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart A,. Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes. J Clin Oncol 2010; 28: 256-63.
9. Yarden Y, Sliwkowski M,. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-37. (Pubitemid 33674041)
10. Normanno N, Bianco C, Strizzi L, Mancino M, Maiello M, De Luca A, Caponigro F, Salomon D,. The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets 2005; 6: 243-57. (Pubitemid 40667793)
11. Price JT, Wilson HM, Haites NE,. Epidermal growth factor (EGF) increases the in vitro invasion, motility and adhesion interactions of the primary renal carcinoma cell line, A704. Eur J Cancer 1996; 32: 1977-82. (Pubitemid 26361694)
12. Ignatoski KM, Maehama T, Markwart SM, Dixon JE, Livant DL, Ethier SP,. ERBB-2 overexpression confers PI 3â kinase-dependent invasion capacity on human mammary epithelial cells. Br J Cancer 2000; 82: 666-74. (Pubitemid 30085206)
13. Lu Z, Jiang G, Blume-Jensen P, Hunter T,. Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase. Mol Cell Biol 2001; 21: 4016-31. (Pubitemid 32476463)
14. Shirk AJ, Kuver R,. Epidermal growth factor mediates detachment from and invasion through collagen I and Matrigel in Capan-1 pancreatic cancer cells. BMC Gastroenterol 2005; 5: 12.
15. Ueno Y, Sakurai H, Tsunoda S, Choo M, Matsuo M, Koizumi K, Saiki I,. Heregulin-induced activation of ErbB3 by EGFR tyrosine kinase activity promotes tumor growth and metastasis in melanoma cells. Int J Cancer 2008; 123: 340-7. (Pubitemid 351842018)
16. Radinsky R, Risin S, Fan D, Dong Z, Bielenberg D, Bucana CD, Fidler IJ,. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res 1995; 1: 19-31.
17. Sasaki T, Nakamura T, Rebhun RB, Cheng H, Hale KS, Tsan RZ, Fidler IJ, Langley RR,. Modification of the primary tumor microenvironment by transforming growth factor alpha-epidermal growth factor receptor signaling promotes metastasis in an orthotopic colon cancer model. Am J Pathol 2008; 173: 205-16. (Pubitemid 351947968)
18. Ho-Pun-Cheung A, Bascoul-Mollevi C, Assenat E, Boissière-Michot F, Bibeau F, Cellier D, Ychou M, Lopez-Crapez E,. Reverse transcription- quantitative polymerase chain reaction: description of a RIN-based algorithm for accurate data normalization. BMC Mol Biol 2009; 10: 31.
19. Barber T, Vogelstein B, Kinzler K, Velculescu V,. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 2004; 351: 2883. (Pubitemid 40051921)
20. He Y, Van't Veer LJ, Mikolajewska-Hanclich I, van Velthuysen MF, Zeestraten ECM, Nagtegaal ID, van de Velde CJH, Marijnen CAM,. PIK3CA mutations predict local recurrences in rectal cancer patients. Clin Cancer Res 2009; 15: 6956-62.
21. Nassif N, Lobo G, Wu X, Henderson C, Morrison C, Eng C, Jalaludin B, Segelov E,. PTEN mutations are common in sporadic microsatellite stable colorectal cancer. Oncogene 2004; 23: 617-28. (Pubitemid 38175018)
22. Karoui M, Tresallet C, Julie C, Zimmermann U, Staroz F, Brams A, Muti C, Boulard C, Robreau A, Puy H, Malafosse R, Penna C, et al. Loss of heterozygosity on 10q and mutational status of PTEN and BMPR1A in colorectal primary tumours and metastases. Br J Cancer 2004; 90: 1230-4. (Pubitemid 38496818)
23. Guy P, Platko J, Cantley L, Cerione R, Carraway K,. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci USA 1994; 91: 8132-6.
24. Berger M, Mendrola J, Lemmon M,. ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface. FEBS Let 2004; 569: 332-6. (Pubitemid 38849407)
25. Shibata T, Kawano T, Nagayasu H, Okumura K, Arisue M, Hamada J, Takeichi N, Hosokawa M,. Enhancing effects of epidermal growth factor on human squamous cell carcinoma motility and matrix degradation but not growth. Tumour Biol 1996; 17: 168-75. (Pubitemid 26151481)
26. Engebraaten O, Bjerkvig R, Pedersen PH, Laerum OD,. Effects of EGF, bFGF, NGF and PDGF(bb) on cell proliferative, migratory and invasive capacities of human brain-tumour biopsies in vitro. Int J Cancer 1993; 53: 209-14. (Pubitemid 23042867)
27. Stumm G, Eberwein S, Rostock-Wolf S, Stein H, Pomer S, Schlegel J, Waldherr R,. Concomitant overexpression of the EGFR and erbB-2 genes in renal cell carcinoma (RCC) is correlated with dedifferentiation and metastasis. Int J Cancer 1996; 69: 17-22. (Pubitemid 26083265)
28. Giralt J, de las Heras M, Cerezo L, Eraso A, Hermosilla E, Velez D, Lujan J, Espin E, Rosello J, Majó J, Benavente S, Armengol M, de Torres I,. The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis. Radiother Oncol 2005; 74: 101-8. (Pubitemid 40331866)
29. Li S, Kim J, Kim J, Cho M, Yoon W, Song K, Yeo S, Kim J,. Epidermal growth factor receptor as a prognostic factor in locally advanced rectal-cancer patients treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 2006; 65: 705-12. (Pubitemid 43795832)
30. Fernebro E, Bendahl P, Dictor M, Persson A, Fernö M, Nilbert M,. Immunohistochemical patterns in rectal cancer: application of tissue microarray with prognostic correlations. Int J Cancer 2004; 111: 921-8. (Pubitemid 39096241)
31. Bertolini F, Bengala C, Losi L, Pagano M, Iachetta F, Dealis C, Jovic G, Depenni R, Zironi S, Falchi AM, Luppi G, Conte PF,. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007; 68: 1455-61. (Pubitemid 47176800)
32. Adams EJ, Green JA, Clark AH, Youngson JH,. Comparison of different scoring systems for immunohistochemical staining. J Clin Pathol 1999; 52: 75-77. (Pubitemid 29023513)
33. Atkins D, Reiffen K, Tegtmeier CL, Winther H, Bonato MS, Störkel S,. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 2004; 52: 893-901. (Pubitemid 38857154)
34. Langner C, Ratschek M, Rehak P, Schips L, Zigeuner R,. Are heterogenous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation? J Clin Pathol 2004; 57: 773-5. (Pubitemid 38901498)
35. Srinivasan R, Poulsom R, Hurst HC, Gullick WJ,. Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. J Pathol 1998; 185: 236-45. (Pubitemid 28320044)
36. Walker RA, Dearing SJ,. Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. Breast Cancer Res Treat 1999; 53: 167-76. (Pubitemid 29161123)
37. Ho-Pun-Cheung A, Cellier D, Lopez-Crapez E,. [Considerations for normalisation of RT-qPCR in oncology.]. Ann Biol Clin (Paris) 2008; 66: 121-9.
38. Ho-Pun-Cheung A, Bascoul-Mollevi C, Assenat E, Bibeau F, Boissière-Michot F, Cellier D, Ychou M, Lopez-Crapez E,. Validation of an appropriate reference gene for normalization of reverse transcription- quantitative polymerase chain reaction data from rectal cancer biopsies. Anal Biochem 2009; 388: 348-50.
39. Bustin S,. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000; 25: 169-93.
40. Dheda K, Huggett J, Chang J, Kim L, Bustin S, Johnson M, Rook G, Zumla A,. The implications of using an inappropriate reference gene for real-time reverse transcription PCR data normalization. Anal Biochem 2005; 344: 141-3. (Pubitemid 41569389)
41. Grivas PD, Antonacopoulou A, Tzelepi V, Sotiropoulou-Bonikou G, Kefalopoulou Z, Papavassiliou AG, Kalofonos H,. HER-3 in colorectal tumourigenesis: from mRNA levels through protein status to clinicopathologic relationships. Eur J Cancer 2007; 43: 2602-11. (Pubitemid 350103546)
42. Rodel C, Martus P, Papadoupolos T, Fuzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, Wittekind C,. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005; 23: 8688-96. (Pubitemid 46211512)
43. Freidlin B, McShane LM, Korn EL,. Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst 2010; 102: 152-60.
44. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040-8. (Pubitemid 350106711)
45. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E,. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45. (Pubitemid 38944402)